Filter Results:
(594)
Show Results For
- All HBS Web
(1,092)
- People (2)
- News (285)
- Research (594)
- Multimedia (12)
- Faculty Publications (244)
Show Results For
- All HBS Web
(1,092)
- People (2)
- News (285)
- Research (594)
- Multimedia (12)
- Faculty Publications (244)
Sort by
- May 2009 (Revised August 2013)
- Case
The DiagnoFirst Opportunity
By: Robert C. Pozen and Rukmini Balu
John Mason, a principle at Oldwell Partners, was facing a decision of whether or not to invest in DiagnoFirst, a molecular diagnostics firm. DiagnoFirst's key product was a genetic test that identified a subset of prostate cancer patients with a high risk of clinical... View Details
Keywords: Genetic Engineering; Genetically Modified; Genomics; Venture Capital; Patents; Genetics; Decision Choices and Conditions; Laws and Statutes; Investment; Science-Based Business; Biotechnology Industry
Pozen, Robert C., and Rukmini Balu. "The DiagnoFirst Opportunity." Harvard Business School Case 309-112, May 2009. (Revised August 2013.)
- August 14, 2020
- Comment
How Has COVID-19 Affected Health Insurance Offered by Small Businesses in the U.S.? Early Evidence from a Survey
By: Leemore S. Dafny, Yin Wei Soon, Zoë Cullen and Christopher T. Stanton
As the COVID-19 pandemic stretches toward its third quarter, loss of health insurance coverage has not figured prominently in the public debate. Data in this report demonstrate why that is, but also suggest that the apparent stability is fragile, with potentially... View Details
Keywords: Health Pandemics; Health Care and Treatment; Insurance; Small Business; Surveys; United States
Dafny, Leemore S., Yin Wei Soon, Zoë Cullen, and Christopher T. Stanton. "How Has COVID-19 Affected Health Insurance Offered by Small Businesses in the U.S.? Early Evidence from a Survey." NEJM Catalyst (August 14, 2020). (Commentary.)
- November 2019
- Article
A Review of Bundled Payments in Total Joint Replacement
By: Olivia Manickas-Hill, Kevin J. Bozic and Thomas W. Feeley
The Bundled Payments for Care Improvement (BPCI) initiative, developed by the U.S. Center for Medicare & Medicaid Innovation, aims to reduce health care expenditures while maintaining or improving patient outcomes.
Several published reports evaluating the impact... View Details
Several published reports evaluating the impact... View Details
Manickas-Hill, Olivia, Kevin J. Bozic, and Thomas W. Feeley. "A Review of Bundled Payments in Total Joint Replacement." Journal of Bone and Joint Surgery Reviews 7, no. 11 (November 2019).
- 07 Dec 2009
- Research & Ideas
Government’s Positive Role in Kick-Starting Entrepreneurship
government in making it a success. "Particularly during the early years, the government played a critical role in shaping Silicon... View Details
- August 2010 (Revised March 2012)
- Case
The UCLA Medical Center: Kidney Transplantation
By: Michael E. Porter, Jennifer F Baron, Jacob Mathew Chacko and Robin Jian Tang
In 2010, organ transplantation remained among the few sets of medical conditions in the U.S. for which bundled payments were a dominant reimbursement model, and for which patient health outcomes were universally measured and reported. In 1986, UCLA Medical Center was... View Details
Keywords: Insurance; Health Care and Treatment; Health Disorders; Measurement and Metrics; Outcome or Result; Competitive Strategy; Integration; Health Industry; California
Porter, Michael E., Jennifer F Baron, Jacob Mathew Chacko, and Robin Jian Tang. "The UCLA Medical Center: Kidney Transplantation." Harvard Business School Case 711-410, August 2010. (Revised March 2012.)
- 2024
- Article
Beyond the 510(k): The Regulation of Novel Moderate-Risk Medical Devices, Intellectual Property Considerations, and Innovation Incentives in the FDA’s De Novo Pathway
By: Mateo Aboy, Cristina Crespo and Ariel Stern
Moderate-risk medical devices constitute 99% of those that have been regulated by the U.S. Food and Drug Administration (FDA) since it gained authority to regulate medical technology nearly five decades ago. This article presents an analysis of the interaction between... View Details
Keywords: Governing Rules, Regulations, and Reforms; Health Care and Treatment; Technology Adoption; Technological Innovation; Safety; Medical Devices and Supplies Industry; United States
Aboy, Mateo, Cristina Crespo, and Ariel Stern. "Beyond the 510(k): The Regulation of Novel Moderate-Risk Medical Devices, Intellectual Property Considerations, and Innovation Incentives in the FDA’s De Novo Pathway." Art. 29. npj Digital Medicine 7 (2024).
- January 2014 (Revised June 2014)
- Case
23andMe: Genetic Testing for Consumers (A)
By: John A. Quelch and Margaret L. Rodriguez
On November 22, 2013, the direct-to-consumer genetic testing provider, 23andMe, received a letter from the U.S. Food and Drug Administration (FDA) ordering the company to halt the sale and promotion of its genetic testing kit. The FDA stated that the product was... View Details
Keywords: Public Health; Genome Testing; Health Care; Ancestry; 23andMe; Marketing; Product Launch; Health; Health Care and Treatment; Health Testing and Trials; Genetics; Strategy; Health Industry; United States
Quelch, John A., and Margaret L. Rodriguez. "23andMe: Genetic Testing for Consumers (A)." Harvard Business School Case 514-086, January 2014. (Revised June 2014.)
- Research Summary
Fairness and Efficiency in Resource Allocation
In studying the relationship of fairness and efficiency, Professor Trichakis takes the novel approach of looking at varied industries for unifying factors, and he pays special attention to inequities by incorporating both quantitative work in social welfare and the... View Details
- Article
Assessing the Food and Drug Administration's Risk-Based Framework for Software Precertification with Top Health Apps in the United States: Quality Improvement Study
By: Noy Alon, Ariel Dora Stern and John Torous
BACKGROUND: As the development of mobile health apps continues to accelerate, the need to implement a framework that can standardize categorizing these apps to allow for efficient, yet robust regulation grows. However, regulators and researchers are faced with numerous... View Details
Keywords: Mobile Health; Smartphone; Food And Drug Administration; Risk-based Framework; Health Care and Treatment; Mobile and Wireless Technology; Applications and Software; Framework
Alon, Noy, Ariel Dora Stern, and John Torous. "Assessing the Food and Drug Administration's Risk-Based Framework for Software Precertification with Top Health Apps in the United States: Quality Improvement Study." JMIR mHealth and uHealth 8, no. 10 (October 2020).
- 02 Oct 2006
- Research & Ideas
Negotiating in Three Dimensions
"interests," or what each side really cares about. Failure to uncover interests often leads to mistakes in our second dimension, deal design, such as treating potentially more cooperative... View Details
Keywords: by Martha Lagace
- February 24, 2022
- Article
Want to Prevent the Next Hospital Bed Crisis? Enlist the SEC
By: Regina E. Herzlinger and Richard Boxer
During the initial phases of the COVID-19 pandemic, many U.S. hospitals could not provide enough beds to meet demand. Solving the problem of inadequate capacity is of utmost importance in the “new normal,” which requires recognizing the ongoing need for hospital-based... View Details
Keywords: COVID; COVID-19 Pandemic; Hospital Capacity; SEC Regulation; Health Pandemics; Crisis Management; Performance Capacity; Planning
Herzlinger, Regina E., and Richard Boxer. "Want to Prevent the Next Hospital Bed Crisis? Enlist the SEC." Harvard Business School Working Knowledge (February 24, 2022).
- September 2014 (Revised May 2017)
- Case
Fresno's Social Impact Bond for Asthma
By: John A. Quelch and Margaret L. Rodriguez
In 2014, Social Impact Bonds (SIBs) were quickly gaining popularity as an investment vehicle which joined together private investors and nonprofits to tackle social issues. Although numerous SIB projects and proposals had cropped up across the U.S. following the launch... View Details
Keywords: Social Enterprise; Health Care; Marketing; Bonds; Financing; Asthma; Air Pollution; Air Quality; Chronic Disease; Public Health; Health; Health Care and Treatment; Finance; Health Industry; Financial Services Industry; United States
Quelch, John A., and Margaret L. Rodriguez. "Fresno's Social Impact Bond for Asthma." Harvard Business School Case 515-028, September 2014. (Revised May 2017.)
- December 2017 (Revised April 2018)
- Case
The Children's Hospital of Philadelphia: Network Strategy 2016
By: Michael E. Porter, Thomas W. Feeley and Toyin J. Okanlawon
Children’s Hospital of Philadelphia (CHOP) began as a stand-alone hospital in the heart of downtown Philadelphia in 1855. By 2016 the CHOP Care Network stretched across Pennsylvania, New Jersey, and the New York metropolitan area, providing a wide range of services... View Details
Keywords: Communication; Health Care and Treatment; Service Delivery; Organizational Structure; Networks; Integration; Strategy; Health Industry; Philadelphia
Porter, Michael E., Thomas W. Feeley, and Toyin J. Okanlawon. "The Children's Hospital of Philadelphia: Network Strategy 2016." Harvard Business School Case 718-420, December 2017. (Revised April 2018.)
- March 2023 (Revised March 2024)
- Case
The Purdue Pharma Bankruptcy: Settling the Opioid Crisis
By: Kristin Mugford, Carin-Isabel Knoop and Susan Pinckney
How to get to a fair outcome for claimants in the Purdue Pharma bankruptcy given its significant role in the U.S. opioid crisis. View Details
Keywords: Regulation; Ethics; Fairness; Insolvency and Bankruptcy; Government Legislation; Courts and Trials; Laws and Statutes; Lawsuits and Litigation; Legal Liability; Crime and Corruption; Negotiation Offer; Negotiation Participants; Negotiation Style; Product Design; Product Development; Brands and Branding; Marketing Strategy; Trust; Government and Politics; Law; Negotiation; Operations; Ownership; Marketing; Social Psychology; Health Care and Treatment; Pharmaceutical Industry; United States
Mugford, Kristin, Carin-Isabel Knoop, and Susan Pinckney. "The Purdue Pharma Bankruptcy: Settling the Opioid Crisis." Harvard Business School Case 223-060, March 2023. (Revised March 2024.)
- August 2012 (Revised January 2013)
- Case
Public Health Insurance Exchanges: The Massachusetts Experience
By: Regina Herzlinger and Jordan Bazinsky
The CEO of Tufts Health Plan, James Roosevelt, is wondering whether to offer insurance products on the Massachusetts Connector, the first U.S. exchange. He wonders if he should enter these uncharted waters at all. And, if yes, with a broad network or a narrow network... View Details
- March 2021 (Revised January 2023)
- Case
The Trouble with TCE
By: Vincent Pons, Rafael Di Tella and Galit Goldstein
Trichloroethylene, or TCE, was a chemical used by tens of thousands of businesses in the United States. It was an affordable tool for many. Yet, TCE had been associated with important health risks, including cancer and autoimmune disease. TCE potentially posed other... View Details
Keywords: Trichloroethylene; Toxicity; Lobbying; Chemicals; Health Disorders; Governing Rules, Regulations, and Reforms; Policy; Ethics; Business and Government Relations; Chemical Industry; United States
Pons, Vincent, Rafael Di Tella, and Galit Goldstein. "The Trouble with TCE." Harvard Business School Case 721-031, March 2021. (Revised January 2023.)
- February 2001 (Revised February 2002)
- Case
Estee Lauder and the Market for Prestige Cosmetics
By: Nancy F. Koehn
Opens with a brief history of the U.S. cosmetics market and its rapid development in the 1920s. Also recounts Lauder's initial involvement in the sector, making skin care products and selling them in Manhattan beauty parlors during the Great Depression. Pays particular... View Details
Keywords: Fluctuation; Organizational Change and Adaptation; Market Entry and Exit; Entrepreneurship; Luxury; Business Strategy; Society; Beauty and Cosmetics Industry; United States
Koehn, Nancy F. "Estee Lauder and the Market for Prestige Cosmetics." Harvard Business School Case 801-362, February 2001. (Revised February 2002.)
- 07 Jun 2016
- First Look
June 7, 2016
strategic, financial, and operational objectives. Publisher's link: https://www.hbs.edu/faculty/Pages/item.aspx?num=51110 May 2016 Oncology How the Affordable Care Act Has Affected View Details
Keywords: Sean Silverthorne
- November 2018
- Case
The National Hockey League
By: Robert F. Higgins, John Masko and James Weber
In 2015, National Hockey League (NHL) commissioner Gary Bettman was weighing two major decisions: whether to expand the league to a new city, and whether to conclude a digital media rights deal with Major League Baseball Advanced Media (MLBAM). Expansion required a... View Details
Keywords: NHL Expansion; Digital Media Rights; Sports; Expansion; Media; Decisions; Sports Industry; Canada
Higgins, Robert F., John Masko, and James Weber. "The National Hockey League." Harvard Business School Case 819-036, November 2018.
- September 2014 (Revised February 2015)
- Case
Pfizer and AstraZeneca: Marketing an Acquisition (A)
By: John A. Quelch and James Weber
In 2014, Pfizer proposed a friendly acquisition of AstraZeneca, but the AstraZeneca board resisted over price and strategy concerns. Was this good for pharmaceutical consumers? Pfizer, like pharmaceutical companies in general, faced difficulties in growing sales due to... View Details
Keywords: Health Care Policy; Mergers And Acquisitions; Marketing; Government Relations; Crisis Management; Decision Making; Growth and Development; Management; Markets; Strategy; Pharmaceutical Industry; United Kingdom; United States
Quelch, John A., and James Weber. "Pfizer and AstraZeneca: Marketing an Acquisition (A)." Harvard Business School Case 515-007, September 2014. (Revised February 2015.)